KBIO COMPANY Inc. (KOSDAQ:038530)
South Korea · Delayed Price · Currency is KRW KBIO COMPANY Statistics
Total Valuation
KBIO COMPANY has a market cap or net worth of KRW 28.41 billion. The enterprise value is 26.62 billion.
| Market Cap | 28.41B |
| Enterprise Value | 26.62B |
Important Dates
The next estimated earnings date is Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KBIO COMPANY has 115.50 million shares outstanding. The number of shares has increased by 1.09% in one year.
| Current Share Class | 115.50M |
| Shares Outstanding | 115.50M |
| Shares Change (YoY) | +1.09% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 77.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.34 |
| PB Ratio | 0.27 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | 4.29 |
| P/OCF Ratio | 4.24 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 37.75, with an EV/FCF ratio of 4.02.
| EV / Earnings | -2.20 |
| EV / Sales | 0.32 |
| EV / EBITDA | 37.75 |
| EV / EBIT | n/a |
| EV / FCF | 4.02 |
Financial Position
The company has a current ratio of 8.44, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.44 |
| Quick Ratio | 7.17 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 1.35 |
| Debt / FCF | 0.14 |
| Interest Coverage | -28.18 |
Financial Efficiency
Return on equity (ROE) is -15.82% and return on invested capital (ROIC) is -0.17%.
| Return on Equity (ROE) | -15.82% |
| Return on Assets (ROA) | -0.16% |
| Return on Invested Capital (ROIC) | -0.17% |
| Return on Capital Employed (ROCE) | -0.30% |
| Revenue Per Employee | 2.12B |
| Profits Per Employee | -309.95M |
| Employee Count | 39 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 14.52 |
Taxes
In the past 12 months, KBIO COMPANY has paid 267.02 million in taxes.
| Income Tax | 267.02M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.19% in the last 52 weeks. The beta is 0.93, so KBIO COMPANY's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -13.19% |
| 50-Day Moving Average | 269.26 |
| 200-Day Moving Average | 260.83 |
| Relative Strength Index (RSI) | 28.77 |
| Average Volume (20 Days) | 361,778 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KBIO COMPANY had revenue of KRW 82.79 billion and -12.09 billion in losses. Loss per share was -105.15.
| Revenue | 82.79B |
| Gross Profit | 12.78B |
| Operating Income | -314.10M |
| Pretax Income | -17.67B |
| Net Income | -12.09B |
| EBITDA | 705.23M |
| EBIT | -314.10M |
| Loss Per Share | -105.15 |
Balance Sheet
The company has 52.65 billion in cash and 952.62 million in debt, giving a net cash position of 51.70 billion or 447.65 per share.
| Cash & Cash Equivalents | 52.65B |
| Total Debt | 952.62M |
| Net Cash | 51.70B |
| Net Cash Per Share | 447.65 |
| Equity (Book Value) | 104.56B |
| Book Value Per Share | 473.11 |
| Working Capital | 60.98B |
Cash Flow
In the last 12 months, operating cash flow was 6.69 billion and capital expenditures -69.41 million, giving a free cash flow of 6.63 billion.
| Operating Cash Flow | 6.69B |
| Capital Expenditures | -69.41M |
| Free Cash Flow | 6.63B |
| FCF Per Share | 57.36 |
Margins
Gross margin is 15.44%, with operating and profit margins of -0.38% and -14.60%.
| Gross Margin | 15.44% |
| Operating Margin | -0.38% |
| Pretax Margin | -21.34% |
| Profit Margin | -14.60% |
| EBITDA Margin | 0.85% |
| EBIT Margin | -0.38% |
| FCF Margin | 8.00% |
Dividends & Yields
KBIO COMPANY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.09% |
| Shareholder Yield | n/a |
| Earnings Yield | -42.55% |
| FCF Yield | 23.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 27, 2017. It was a reverse split with a ratio of 0.1.
| Last Split Date | Apr 27, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
KBIO COMPANY has an Altman Z-Score of 2.81 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.81 |
| Piotroski F-Score | 3 |